Compugen appoints Dr. Michal Preminger to Board of Directors

Compugen Ltd board of directors has appointed Michal Preminger (PhD, MBA, Executive Director at Harvard University Office of Technology Development’s Harvard Medical School site) as Director.

Prior she worked at Harvard Office of Technology Development, she has negotiated a multitude of licensing and strategic alliance agreements with pharmaceutical and biotechnology companies. Prior to joining Harvard in 2005, Dr. Preminger held a number of senior executive business development and R&D positions in technology and biotechnology companies, including at Compugen, where she was a member of the management team that took the Company public in August 2000. Dr. Preminger is a member of the board of directors of BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at FutuRx (a partnership between Takeda Pharmaceuticals, Johnson & Johnson and Orbimed Ventures) and Prize4Life.She holds an undergraduate degree in Medicine from the Hebrew University of Jerusalem’s School of Medicine, MSc and PhD from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.

Compugen President and CEO, Anat Cohen-Dayag said that they are delighted to welcome Dr. Preminger to the Company as a member of the Board. They look forward to benefitting from Dr. Preminger’s broad business experience across the pharma and biotech industries, as they continue to focus on the various therapeutic and business opportunities presented by their pipeline and their unique discovery capabilities.